Oral small molecule, ELP-004, inhibits bone erosions in model of rheumatoid arthritis (RA) Our new publication reveals that the small molecule ELP-004 preferentially inhibits transient receptor potential canonical?(TRPC) channels and potently interferes with osteoclast maturation driven by inflammatory cytokines TNFα or LTB4, but not RANKL. We further show that ELP-004 reduces bone erosions in a mouse model of rheumatoid arthritis (RA). Our data identify TRPC channels as critical mediators of inflammatory bone erosion and provide insight into the major target of ELP-004, a drug currently in preclinical testing as a therapeutic for inflammatory arthritis. Full text available today in #ScienceAdvances: https://lnkd.in/eJvkmZt4 #rheumatoidarthritis #science #research #pharma
ExesaLibero Pharma
制药业
Morgantown，West Virginia 47 位关注者
Dedicated to developing new small molecule drugs to treat bone disease.
关于我们
The company is working on a new approach to treating bone erosion based on a common pathway in the cell that infiltrates bone and joints. The primary mission ExesaLibero Pharma, Inc is to complete the vital preclinical toxicology and efficacy studies for a groundbreaking small-molecule drug. This extraordinary innovation holds the key to controlling the insidious bone erosion that plagues numerous debilitating diseases, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis. By tackling this critical issue head-on, we aim to enhance the lives of countless individuals afflicted by these disease conditions. The results of these studies will form the bases for an Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, we expect to initiate clinical trials that will lead to full approval of the drug for clinical use.
- 网站
-
https://www.exesalibero-pharma.com
ExesaLibero Pharma的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Morgantown，West Virginia
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Drug Development、Bone erosion、ELP-004、Small Molecule Drugs和Arthritis
地点
-
主要
获取路线
781 Chestnut Ridge Rd
Suite 400
US，West Virginia，Morgantown，26505
ExesaLibero Pharma员工
动态
-
We are excited to share our mission patch! On November 4, 2024, we launched ELP-004, on #CRS31. ELP-004 is a small molecule used to treat bone erosion. In collaboration with Redwire Space, we are using PIL-BOX to crystalize ELP-004 in microgravity aboard the International Space Station National Laboratory. Studying crystals that aren't distorted by gravity can help us develop medicines that are more effective with fewer side effects.
??? The ExesaLibero Pharma mission patch celebrates groundbreaking research by ExesaLibero Pharma and Redwire launching on #CRS31! This mission, using PIL-BOX as the ultimate pharma lab in space, will explore new bone health treatments with the potential to benefit human health on Earth and support safer, long-term space missions for astronauts. ?? What does the mission patch represent? ?? Bone Health Focus: Bone and pill shapes symbolize the mission’s commitment to advancing bone health. ?? Spirit of Exploration: Embodying the adventurous spirit of space research, with a fun Halloween twist — a pumpkin head! ?? Mission Colors: Featuring a blend of Redwire and ExesaLibero’s signature colors.
-
In partnership with Redwire Space, we are crystallizing ELP-004 in microgravity at the International Space Station National Laboratory. This project launched on November 4, 2024, on #CRS31 with the goal of advancing pharmaceutical research for treating bone erosions.
?? During a pre-launch media call hosted by International Space Station National Laboratory, Dr. John Barrett, President and Chief Scientific Officer at ExesaLibero Pharma, shared how the PIL-07 investigation is unlocking new possibilities for bone health. Crystallizing ELP-004 aboard the ISS could lead to breakthroughs in treating bone loss, benefiting patients on Earth and supporting astronaut health on long-duration missions. ???? #CRS31 #PIL07 #SpacePharma #ExesaLiberoPharma #RedwireSpace #MissionEarth
-
We are excited to share our recent article in Pharmaceutical Research & Perspectives characterizing ELP-004, a small molecule, osteoclast inhibitor in development for the treatment of bone erosion. https://lnkd.in/e9_APPWT